Pneumococcal conjugate vaccines in Taiwan: optimizing health gains in children and older adults through constrained optimization modeling: Pneumococcal conjugate vaccines optimization in Taiwan.
Taiwan
constrained optimization model
pneumococcal disease
public health
vaccine
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
06
09
2021
revised:
27
10
2021
accepted:
30
10
2021
pubmed:
9
11
2021
medline:
5
1
2022
entrez:
8
11
2021
Statut:
ppublish
Résumé
Budgetary constraints force healthcare authorities to set priorities for optimal vaccine interventions. A comprehensive decision-making tool would help inform the best combination and sequence of introduction of vaccines within constrained budgets. Looking at available vaccines against pneumococcal infections in Taiwan (10/13-valent pneumococcal conjugate vaccines [PCV10, PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPV23]), a constrained optimization (CO) model was used to assess the optimal combination of vaccines in children and older adults that would maximize the quality-adjusted life years under predefined budget constraints. Scenario analyses were carried out to evaluate the impact of vaccine efficacy (VE) on the optimized solution. The CO model demonstrated that the optimal sequence of vaccine introduction was PPV23 in older adults and PCV10 in children. The optimal solution was mostly driven by the potential to reduce disease burden in the older adult population. The VE of PPV23 in older adults and the VE of PCV vaccines against serotype 19A invasive pneumococcal disease had little impact on the optimal solution. The CO approach can be used to set priorities for introducing new vaccines while maximizing health gains per age group within the constrained National Vaccine Fund for the prevention of pneumococcal disease in Taiwan.
Identifiants
pubmed: 34749009
pii: S1201-9712(21)00851-1
doi: 10.1016/j.ijid.2021.10.058
pii:
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-164Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest CYL received consultation fees from the Taiwan Society for Pharmacoeconomics and Outcome Research. TF and YFH are employees of the GSK group of companies, and YFH hold shares in the GSK group of companies. CHT and RFP report no conflicts of interest (financial or non-financial). CYL, TF, and YFH have no non-financial conflicts of interest to declare.